A novel topical formulation of a selective JAK inhibitor has advanced to Phase 3 clinical trials for the treatment of alopecia areata, following encouraging Phase 2 data demonstrating meaningful hair regrowth with minimal systemic side effects.

Why Topical Matters

While oral JAK inhibitors have already been approved for alopecia areata, a topical formulation could offer similar efficacy with fewer systemic risks, making it suitable for a broader patient population including those with mild-to-moderate disease.

Phase 2 Results

In the Phase 2 study, 40% of patients using the topical formulation achieved at least 50% hair regrowth (SALT50) at 24 weeks, compared to 12% in the vehicle control group.

Next Steps

The Phase 3 program will enroll approximately 1,500 patients across 100 clinical sites worldwide, with results expected in late 2027.